CN101445468A - Method for preparing para aminobenzoic acid quasi dipeptide ester and application thereof - Google Patents
Method for preparing para aminobenzoic acid quasi dipeptide ester and application thereof Download PDFInfo
- Publication number
- CN101445468A CN101445468A CNA2008102372450A CN200810237245A CN101445468A CN 101445468 A CN101445468 A CN 101445468A CN A2008102372450 A CNA2008102372450 A CN A2008102372450A CN 200810237245 A CN200810237245 A CN 200810237245A CN 101445468 A CN101445468 A CN 101445468A
- Authority
- CN
- China
- Prior art keywords
- para
- benzoic acid
- ester
- amino
- amino benzoic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses para aminobenzoic acid quasi dipeptide ester, wherein, when R<1>is Bzl, R<2>is Me; and when R<1> is H, CH (CH3)2, CH2CH (CH3)2, CH (CH3) CH2CH3, CH2OBzl, CH2COOBzl or CH2CH2COOBzl, R<2> is Bzl. The invention also discloses a method for preparing para aminobenzoic acid quasi dipeptide ester, namely para aminobenzoic acid and amino-acid ester are directly coupled in the presence of coupling agent and coupling assistant, the method is simple, the reaction condition is mild, the operation is convenient, products can be easily purified, and the yields are high; the para aminobenzoic acid quasi dipeptide ester of the invention has an anti-diabetic activity, can be used for preparing antidiabetic medicine, and has potential applications.
Description
Technical field
The present invention relates to a kind of organic compound, particularly a kind of para-amino benzoic acid quasi dipeptide ester also relates to the preparation method and the application of this para-amino benzoic acid quasi dipeptide ester.
Background technology
Diabetes are the worldwide public health problems that have a strong impact on human health and quality of life.In recent years, along with the raising of people's living standard, the increase of aging population and fat incidence, the sickness rate of diabetes is ascendant trend year by year.International diabetes epidemiological study in 2003 shows, the diabetic subject that has made a definite diagnosis in the whole world is about 1.94 hundred million, expect global diabetic subject in 2025 and will be increased to 3.33 hundred million, it is nearly 72% to rise, and wherein Africa, Middle East, the West Pacific Ocean that comprises China and the Asian-Pacific area and Hispanic diabetes rate of growth all will be above global average growth rates.At present, diabetes have become the third-largest Non Communicable Diseases (NCD) of developing country after cardiovascular disorder and tumour, have brought white elephant to social and economic development.Therefore, the study on prevention of diabetes has crucial meaning, the clinical especially an urgent demand of development of the evident in efficacy and antidiabetic medicine that toxic side effect is low.
At present, the antidiabetic medicine of bibliographical information is of a great variety and type is different.The contriver discovers, the derivative of the Nateglinide of phenylpropionic acid class, the Meglitinide of benzoic acids and Repaglinide, alpha-alkoxy-beta-phenyl propionic acid, L-tyrosine analog derivative and contain in the alpha-glucosidase inhibitor equimolecular of cinnamide analog derivative and all contain carboxyl and amino point out these 2 kinds of functional groups to have a very important role in the antidiabetic medicine molecule.For this reason, the contriver has synthesized a large amount of beta-amino ketones analog derivatives and it has been carried out the antidiabetic medicine model discrimination, and result of study shows to have the structural unit that active a lot of molecule all exists para-amino benzoic acid or para-amino benzoic acid ester.
Summary of the invention
In view of this, in order to probe into the structure activity relationship of medicines structure and anti-diabetic activity, for the research and development of antidiabetic thing provide a kind of new research direction and a kind of research object that has than the great development application potential, satisfy clinically in the active demand evident in efficacy and antidiabetic medicine that toxic side effect is low, first purpose of the present invention is to provide a kind of para-amino benzoic acid quasi dipeptide ester with anti-diabetic activity.
For reaching this purpose, para-amino benzoic acid quasi dipeptide ester of the present invention, form by following formula:
Wherein, work as R
1During for Bzl, R
2Be Me; Work as R
1Be H, CH
3, CH (CH
3)
2, CH
2CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2OBzl, CH
2COOBzl or CH
2CH
2During COOBzl, R
2Be Bzl.Me represents methyl, and Bzl represents benzyl.
Second purpose of the present invention is to provide a kind of method for preparing described para-amino benzoic acid quasi dipeptide ester, has that method is simple, reaction conditions is gentle, easy to operate, product is easy to purifying, yield advantages of higher.
For reaching this purpose, the method of the described para-amino benzoic acid quasi dipeptide ester of preparation of the present invention, be with para-amino benzoic acid 1 and amino acid ester 2 directly coupling in the presence of coupling agent and coupling auxiliary agent, make para-amino benzoic acid quasi dipeptide ester 3, its chemical equation is as follows:
In above-mentioned chemical equation, work as R
1During for Bzl, R
2Be Me; Work as R
1Be H, CH
3, CH (CH
3)
2, CH
2CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2OBzl, CH
2COOBzl or CH
2CH
2During COOBzl, R
2Be Bzl.
Further, described coupling agent is N, N '-DIC (DIC), N, N '-dicyclohexylcarbodiimide (DCC), N-ethyl-N '-dimethylamine propyl carbodiimide (EDC), O-benzotriazole-N, N, N ', N '-tetramethyl-urea Tetrafluoroboric acid ester (TBTU) or block special condensing agent (BOP);
Further, described coupling auxiliary agent is 1-hydroxy benzo triazole (HOBt), N-hydroxyl-7-azo benzotriazole (HOAt) or N-maloyl imines (HOSu);
Further, described coupling temperature is 10～35 ℃.
In the methods of the invention, described raw material amino acid ester can be prepared according to techniques well known, is about to amino acid and makes with alcohol generation esterification in the presence of catalyzer.Described catalyzer can be selected from hydrogenchloride, hydrogen bromide, hydrogen iodide, sulfuric acid, sulfur oxychloride, tosic acid, resin, biological enzyme or zeolite etc.
The 3rd purpose of the present invention is to provide the application of described para-amino benzoic acid quasi dipeptide ester in the preparation antidiabetic medicine.
The anti-diabetic activity result of study shows that para-amino benzoic acid quasi dipeptide ester of the present invention has certain anti-diabetic activity.The para-amino benzoic acid quasi dipeptide ester of significant quantity can with pharmaceutically acceptable carrier combinations, make the antidiabetic medicine single preparations of ephedrine; Perhaps, with other natural plant extracts and/or chemical synthetic drug and pharmaceutically acceptable carrier combinations, make the antidiabetic drug compound pharmaceutical with anti-diabetic activity.Those of ordinary skills can determine pharmaceutical dosage form at an easy rate, as tablet, capsule, granule, oral liquid, injection liquid, quick-release and sustained release preparation etc., and are prepared according to the ordinary method of pharmaceutical field.The gained pharmaceutical preparation can be used by any approach easily, comprises approach such as subcutaneous, oral, intramuscular or endoperitoneal.
Beneficial effect of the present invention is:
(1) the invention discloses a kind of para-amino benzoic acid quasi dipeptide ester with anti-diabetic activity, by probing into the structure activity relationship of para-amino benzoic acid quasi dipeptide ester structure and anti-diabetic activity, for the research and development of antidiabetic thing have indicated a new research direction, and a kind of research object that has than the great development application potential is provided, has been expected to it is developed further into and is the antidiabetic thing.
(2) the invention discloses a kind of method for preparing described para-amino benzoic acid quasi dipeptide ester.
The preparation method of the amino acid ester derivative of (replacement) para-amino benzoic acid of bibliographical information mainly is divided into two kinds: first method is to be starting raw material with (replacement) para-amino benzoic acid, for avoiding the generation of side reaction, earlier the amino of (replacement) para-amino benzoic acid is protected, with the amino acid ester derivative coupling, remove amino protecting group at last again; Second method is to be starting raw material with (replacement) p-nitrobenzoic acid, earlier (replacement) p-nitrobenzoic acid is converted into acyl chlorides, again with the amino acid ester derivative coupling, reduces nitro at last.Above-mentioned two kinds of methods are multistep processes, have shortcomings such as complex operation, total recovery are lower, production cost height.
The contriver discovers, when para-amino benzoic acid directly carried out protection such as amino Boc-or Fmoc-, reaction can not be carried out usually smoothly; Find also that simultaneously under the promotion of coupling agent and coupling auxiliary agent, amino unprotected para-amino benzoic acid can comparatively successfully obtain corresponding coupled product with amino acid ester.Therefore; the inventive method is a raw material with the unprotected para-amino benzoic acid of amino; itself and amino acid ester direct coupling in the presence of coupling agent and coupling auxiliary agent are made the para-amino benzoic acid quasi dipeptide ester; be single stage method; omitted reactions steps such as amido protecting in the multistep processes, deprotection or nitroreduction, had that method is simple, reaction conditions is gentle, easy to operate, product is easy to purifying, yield advantages of higher.
(3) the invention discloses the application of described para-amino benzoic acid quasi dipeptide ester in the preparation antidiabetic medicine, have the potential using value.
Embodiment
In order to make the purpose, technical solutions and advantages of the present invention clearer, below the preferred embodiments of the present invention are described in detail.
One, the preparation of para-amino benzoic acid quasi dipeptide ester and evaluation
1, the preparation of amino acid ester
(1) preparation of phenylalanine methyl ester
Get anhydrous methanol 300mL, under condition of ice bath, stir and make cooling, slowly dripping thionyl chloride 130mmol, dropwising the back continues to stir 0.5 hour under condition of ice bath, add L-phenylalanine 100mmol, at room temperature stir and spend the night, again in 65 ℃ of back flow reaction of temperature, finish with thin-layer chromatography (TLC) method monitoring reaction process to reaction, be cooled to room temperature, underpressure distillation is to doing resistates methyl alcohol-anhydrous diethyl ether mixed solvent recrystallization, suction filtration, filter residue is put P
2O
5Middle vacuum-drying promptly gets phenylalanine methyl ester hydrochloride (2a, HClNH
2CH (Bzl) CO
2Me), yield 92.0%, 156.5～158.6 ℃ of fusing points.
(2) preparation of amino-acid benzyl ester
Take by weighing L-amino acid and tosic acid, add benzylalcohol, stirring, heating make dissolving, add toluene again, the reflux water-dividing reaction finishes with TLC method monitoring reaction process to reaction, is cooled to room temperature, freezing placement is spent the night, suction filtration, filter residue washs with anhydrous diethyl ether, alcohol-ether mixed solvent recrystallization, suction filtration, filter residue is put P
2O
5Middle vacuum-drying promptly gets the amino-acid benzyl ester tosilate.The preparation condition and the experimental result of each amino-acid benzyl ester tosilate are as shown in table 1.
The preparation condition of table 1, each amino-acid benzyl ester tosilate and experimental result
*With L-H
2NCH (CH
2OBzl) COOH is a raw material
2, the preparation of para-amino benzoic acid quasi dipeptide ester
Take by weighing self-control phenylalanine methyl ester hydrochloride or amino-acid benzyl ester tosilate 5mmol, add tetrahydrofuran (THF) (THF) 2mL, drip triethylamine 2mL, stir under the room temperature and made dissolving in 30 minutes, make amino acid ester solution; Take by weighing para-amino benzoic acid 5mmol and coupling auxiliary agent (HOBt, HOAt or HOSu) 5.5mmol, add THF2mL and make dissolving, add coupling agent (DIC, DCC, EDC, TBTU or BOP) 6mmol again, stir after 15 minutes under the room temperature, add above-mentioned amino acid ester solution, stirring reaction at room temperature, finish with TLC method monitoring reaction process to reaction, suction filtration, filter residue washs with ethyl acetate, merging filtrate and washing lotion, and underpressure distillation is to doing, the resistates acetic acid ethyl dissolution is the NaHCO of 0.5mol/L through saturated NaCl solution and concentration more successively
3Solution washing, anhydrous Na
2SO
4After the drying, suction filtration, filtrate decompression concentrates, and adds sherwood oil, waits to precipitate and separates out complete back suction filtration, and filter residue is put P
2O
5Middle vacuum-drying promptly gets the para-amino benzoic acid quasi dipeptide ester, adopts recrystallization or column chromatographic isolation and purification in case of necessity.The preparation condition and the experimental result of part para-amino benzoic acid quasi dipeptide ester are as shown in table 2.
The preparation condition and the experimental result of table 2, part para-amino benzoic acid quasi dipeptide ester
Gained para-amino benzoic acid quasi dipeptide ester adopts accurate micro melting point apparatus (X-6 type respectively, Beijing Fu Kai Instr Ltd.), digital automatic polarimeter (WZZ-2S type, Shanghai Precision Scientific Apparatus Co., Ltd), NMR spectrometer with superconducting magnet (AV-300 type, USA; TMS is interior mark, CDCl
3Be solvent), Fourier transform infrared spectrometer (GX type, USA; The KBr compressing tablet), (Agilent 1946B ESI-MS, USA) (Bruker Daltonics Data Analysis 3.2 USA) has carried out structural characterization to electrospray mass spectrometer, proves conclusively consistent with the target product structure with the high resolution electrospray mass spectrometer.The fusing point of each para-amino benzoic acid quasi dipeptide ester (m.p.), specific rotation (
), proton nmr spectra (
1H-NMR), carbon-13 nmr spectra (
13C-NMR), infrared spectra (IR), electrospray ionization mass spectrum (ESI-MS) and high resolution electrospray ionization mass spectrum (HR ESI-MS) measurement result are as follows:
3a[2-(4-amino benzoyl) phenylalanine methyl ester]: m.p.144.3～148.1 ℃;
-0.095 (c 4mg/mL, EtOAc);
1H-NMR δ
H: 3.10～3.23 (m, 2H, CH
2), 3.68 (s, 3H, CH
3), 4.97～5.03 (dd, 1H, J=5.64,12.83Hz, CH), 6.36 (d, 1H, J=7.08Hz, CONH), 6.56 (d, 2H, J=8.41Hz, Ar-H), 7.05 (d, 2H, J=6.37Hz, Ar-H), 7.49 (d, 2H, J=8.41Hz, Ar-H), 7.23 (d, 1H, J=5.96Hz, Ar-H), 7.18 (d, 1H, J=6.61Hz, Ar-H);
13C-NMR δ: 172.44,166.68 (2C=O), 150.07,136.14,129.44,128.90,128.64,127.16,123.19,114.15 (2Ar-), 53.48 (NHCH), 52.40 (OCH
3), 38.08 (CH
2); IR (v/cm
-1): 3384,3343,1742,1630,1607,1502,1184,1218,844,772,699; ESI-MS:299 ([M+H]
+), 321 ([M+Na]
+); HRESI-MS:C
17H
18N
2NaO
3The molecular weight calculated value be 321.1210, measured value is 321.1205.
3b[2-(4-amino benzoyl) glycine benzyl ester]: m.p.146.0～151.3 ℃;
1H-NMR δ
H: 4.25 (d, 2H, J=5.03Hz, CH
2), 5.16 (s, 2H, OCH
2), 6.40 (s, 1H, NH), 6.65 (d, 2H, J=8.42Hz, Ar-H), 7.37 (s, 5H, Ar-H), 7.63 (d, 2H, J=8.41Hz, Ar-H);
13C-NMR δ: 170.42,167.32 (2C=O), 150.02,135.35,129.00,128.75,128.62,128.44,123.30,114.22 (2Ar-), 67.30 (O-CH
2), 41.94 (NHCH
2); IR (v/cm
-1): 3452,3414,3335,1754,1638,1598,1499,1295,1180,844,744,697; ESI-MS:285 ([M+H]
+), 307 ([M+Na]
+); HRESI-MS:C
16H
16N
2NaO
3The molecular weight calculated value be 307.1053, measured value is 307.1045.
3c[2-(4-amino benzoyl) alanine benzyl ester]: m.p.185.8～189.5 ℃;
+ 0.445 (c 2mg/mL, EtOAc);
1H-NMR δ
H: 1.50 (d, 3H, J=7.1Hz, CH
3), 4.78～4.88 (m, 1H, CH), 5.16～5.25 (dd, 2H, J=12.33,15.66Hz ,-OCH
2), 6.58 (d, 1H, J=6.86Hz, CONH), 6.65 (d, 2H, J=8.47Hz, Ar-H), 7.36 (s, 5H, Ar-H), 7.63 (d, 2H, J=8.49Hz, Ar-H);
13C-NMR δ: 173.50,166.71 (2C=O), 149.95,135.51,128.97,128.74,128.53,128.22,123.44,114.21 (2Ar-), 67.25 (OCH
2), 48.56 (NHCH), 18.86 (CH
3); IR (v/cm
-1): 3441,3323,1744,1629,1605,1502,1167,849,742,698; ESI-MS:299 ([M+H]
+), 321 ([M+Na]
+); HRESI-MS:C
17H
18N
2NaO
3The molecular weight calculated value be 321.1210, measured value is 321.1204.
3d[2-(4-amino benzoyl) Xie Ansuan benzyl ester]: m.p.141.2～144.3 ℃;
+ 0.450 (c 2mg/mL, EtOAc);
1H-NMR δ
H: 0.91～0.98 (m, 6H, CH
3), 2.21～2.32 (m, 1H, CH), 4.79～4.84 (m, 1H, CH), 5.14～5.25 (dd, 2H, J=12.20,21.17Hz, OCH
2), 6.49 (d, 1H, J=8.41Hz, CONH), 6.66 (d, 2H, J=8.31Hz, Ar-H), 7.36 (s, 5H, Ar-H), 7.64 (d, 2H, J=8.30Hz, Ar-H);
13C-NMR δ: 172.33,167.02 (2C=O), 149.83,135.30,128.81,128.56,128.39,128.32,123.47,114.06 (2Ar-), 67.01 (OCH
2), 57.18 (NHCH), 31.66 (CH), 18.99,17.79 (CH
3); IR (v/cm
-1): 3449,3310,1730,1630,1502,1181,845,745,698; ESI-MS:327 ([M+H]
+), 349 ([M+Na]
+); HRESI-MS:C
19H
22N
2NaO
3The molecular weight calculated value be 349.1523, measured value is 349.1529.
3e[2-(4-amino benzoyl) leucine benzyl ester]: m.p.144.0～151.0 ℃;
+ 0.220 (c 2mg/mL, EtOAc);
1H-NMR δ
H: 0.93～0.96 (m, 6H, 2CH
3), 1.61～1.76 (m, 3H, CHCH
2), 4.85～4.92 (m, 1H, CH), 5.18 (s, 2H, OCH
2), 6.39 (d, 1H, J=8.03Hz, CONH), 6.65 (d, 2H, J=8.36Hz, Ar-H), 7.35 (s, 5H, Ar-H), 7.62 (d, 2H, J=8.36Hz, Ar-H);
13C-NMR δ: 173.36,166.84 (2C=O), 149.74,135.38,128.82,128.54,128.32,128.14,123.34,114.10 (2Ar-), 66.99 (OCH
2), 51.06 (NHCH), 41.83 (CH
2), 34.91 (CH), 22.81,22.03 (2CH
3); IR (v/cm
-1): 3443,3351,1741,1628,1605,1499,1163,848,733,696; ESI-MS:341 ([M+H]
+); HRESI-MS:C
20H
24N
2NaO
3The molecular weight calculated value be 363.1679, measured value is 363.1662.
3f[2-(4-amino benzoyl) Isoleucine benzyl ester]: m.p.133.7～137.9 ℃;
+ 0.227 (c2.2mg/mL, EtOAc);
1H-NMR δ
H: 0.88～0.95 (m, 6H, 2CH
3), 1.18～1.46 (m, 2H, C
H 2CH
3), 1.97～2.01 (m, 1H, CH), 4.83～4.86 (m, 1H, CH), 5.14～5.25 (dd, 2H, J=12.22,23.41Hz, OCH
2), 6.51 (d, 1H, J=8.34Hz, CONH), 6.66 (d, 2H, J=8.50Hz, Ar-H), 7.63 (s, 5H, Ar-H), 7.63 (d, 2H, J=8.48Hz, Ar-H);
13C-NMR δ: 172.45,167.05 (2C=O), 149.98,135.45,128.95,128.70,128.54,128.46,123.59,114.23 (2Ar-), 67.13 (O-CH
2), 56.78 (NHCH), 38.47 (CH), 23.59 (CH
2), 15.64,11.72 (2CH
3); IR (v/cm
-1): 3448,3336,1728,1627,1574,1502,1179,1152,845,736,697; ESI-MS:341 ([M+H]
+), 363 ([M+Na]
+); HRESI-MS:C
20H
24N
2NaO
3The molecular weight calculated value be 363.1679, measured value is 363.1691.
3g[2-(4-amino benzoyl) Serine benzyl ester]: m.p.124.8～129.0 ℃;
+ 0.210 (c 2mg/mL, EtOAc);
1H-NMR δ
H: 3.77～4.02 (m, 2H, CH
2), 4.43～4.54 (dd, 2H, J=12.14,20.60Hz, OCH
2), 4.99～5.01 (m, 1H, CH), 5.16～5.27 (dd, 2H, J=12.29,19.97Hz, OCH
2), 6.66 (d, 2H, J=8.43Hz, Ar-H), 6.87 (d, 1H, J=7.96Hz, CONH), 7.25～7.32 (m, 10H, Ar-H), 7.64 (d, 2H, J=8.41Hz, Ar-H);
13C-NMR δ: 170.56,166.83 (2C=O), 149.87,137.48,135.34,128.97,128.53,128.39,128.32,128.12,127.77,127.59,123.18,114.05 (3Ar-), 73.30,70.07 (2O-CH
2), 67.23 (CH
2O-), 53.04 (NHCH); IR (v/cm
-1): 3443,3333,1735,1632,1604,1504,1182,848,741,697; ESI-MS:405 ([M+H]
+), 427 ([M+Na]
+); HRESI-MS:C
24H
24N
2NaO
4The molecular weight calculated value be 427.1628, measured value is 427.1619.
3h[2-(4-amino benzoyl) aspartic acid dibenzyl ester]: m.p.96.9～99.9 ℃;
+ 0.051 (c3.9mg/mL, EtOAc);
1H-NMR δ
H: 2.97～3.21 (m, 2H,
CH 2 COOR), 3.99 (br s, 2H, NH
2), 4.99～5.12 (m, 3H, CH, OCH
2), 5.18 (s, 2H, OCH
2), 6.64 (d, 2H, J=8.45Hz, Ar-H), 7.00 (d, 1H, J=7.63Hz, CONH), 7.28～7.33 (m, 10H, 2Ar-H), 7.56 (d, 2H, J=8.45Hz, Ar-H);
13C-NMR δ: 171.03,166.80 (3C=O), 150.08,135.49,135.37,129.09,128.72,128.53,128.44,128.37,123.20,114.20 (3Ar-), 67.64,66.89 (2OCH
2), 49.11 (NHCH), 36.75 (CH
2); IR (v/cm
-1): 3445,3348,1740,1625,1604,1500,1179,1159,848,732,698; ESI-MS:433 ([M+H]
+), 455 ([M+Na]
+); HRESI-MS:C
25H
24N
2NaO
5The molecular weight calculated value be 455.1577, measured value is 455.1571.
3i[2-(4-amino benzoyl) L-glutamic acid dibenzyl ester]: m.p.119.1～123.6 ℃;
+ 0.060 (c 4mg/mL, EtOAc);
1H-NMR δ
H: 2.13～2.37 (m, 2H, CHC
H 2 ), 2.43～2.52 (m, 2H, CH
2CO), 4.03 (br s, 2H, NH
2), 4.82～4.86 (m, 1H, CH), 5.06 (s, 2H, OCH
2), 5.19 (s, 2H, OCH
2), 6.65 (d, 2H, J=8.40Hz, Ar-H), 6.78 (d, 1H, J=7.63Hz, NH), 7.32 (m, 10H, 2Ar-H), 7.63 (d, 2H, J=8.41Hz, Ar-H);
13C-NMR δ: 173.03,172.09,166.86 (3C=O), 149.90,135.58,135.20,128.91,128.60,128.52,128.44,128.23,122.96,114.05 (3Ar), 67.30,66.56 (2OCH
2), 52.13 (NHCH), 30.39,27.30 (CH
2CH
2); IR (v/cm
-1): 3439,3342,1731,1629,1605,1502,1180,848,739,697; ESI-MS:447 ([M+H]
+), 469 ([M+Na]
+); HRESI-MS:C
26H
26N
2NaO
5The molecular weight calculated value be 469.1734, measured value is 469.1702.
Discover that the preparation of para-amino benzoic acid quasi dipeptide ester mainly is subjected to following factor affecting:
(1) temperature of reaction
The linked reaction of para-amino benzoic acid and amino acid ester, when temperature of reaction was higher, speed of response was very fast, but may cause the generation of side reaction such as racemization; When temperature of reaction was low, speed of response was slower, and side reaction is less; Result of study shows that the linked reaction of para-amino benzoic acid and amino acid ester all can be carried out preferably in 10～35 ℃ of scopes of temperature, and along with temperature of reaction reduces, product purity raises, and aftertreatment is easier.
(2) coupling agent and coupling auxiliary agent
Coupling agent and coupling auxiliary agent are most important to the preparation of para-amino benzoic acid quasi dipeptide ester.Known coupling agent and coupling auxiliary agent all can be used for the linked reaction of para-amino benzoic acid and amino acid ester during polypeptide was synthetic.The contriver is in the research of preparation para-amino benzoic acid quasi dipeptide ester, coupling agent DIC, DCC, EDC, TBTU and BOP have been tried out, and coupling auxiliary agent HOBt, HOAt and HOSu, find by simultaneous test, when coupling agent be DIC or DCC, when the coupling auxiliary agent is HOBt, the linked reaction of most amino acid esters and para-amino benzoic acid can obtain better effects, the reaction times is shorter, aftertreatment is more convenient, and yield is higher.
Two, the anti-diabetic activity of para-amino benzoic acid quasi dipeptide ester is identified
Molecular pharmacology studies show that peroxisome proliferation-activated receptors (PPAR) is the important target spot of treatment type ii diabetes.At present, the PPAR agonist is the very active field of antidiabetic medicine research.
The PPAR agonist activity of para-amino benzoic acid quasi dipeptide ester of the present invention adopts PPRE-Luc reporter gene screening experiment to identify: human liver cancer cell (HepG2) is inoculated in 96 orifice plates overnight incubation; To contain peroxisome proliferation response element (peroxisome proliferatorresponse element with transfection reagent with reference to specification sheets, PPRE) and the plasmid transfection of luciferase (Luc) reporter gene go into the HepG2 cell, cultivate and use the low sugar DMEM substratum that contains para-amino benzoic acid quasi dipeptide ester of the present invention after 24 hours instead, continue to cultivate the activity that detects luciferase after 24 hours, with chemiluminescence intensity L value representation; Normal control (cell of untransfected), model contrast (cells transfected, but do not add testing sample) and positive control (antidiabetic medicine acarbose) are set simultaneously; According to the chemiluminescence intensity L value that records, calculate exciting rate (%) according to the following equation: exciting rate (%)=[(L
Sample/positive control-L
Normal control)/(L
The model contrast-L
Normal control)-1] * 100.
The PPAR agonist activity measurement result of part para-amino benzoic acid quasi dipeptide ester is as shown in table 3.
The PPAR agonist activity measurement result of table 3, part para-amino benzoic acid quasi dipeptide ester
As seen from table, the PPAR agonist activity of 3g is best, the PPAR agonist activity of 3a, 3c and 3i is close, the agonist activity of 3d, 3e and 3f reduces successively, the spatial volume that shows as the para-amino benzoic acid quasi dipeptide ester is more little, the PPAR agonist activity is low more, and this may be relevant with the space structure of its action target spot.
Explanation is at last, above embodiment is only unrestricted in order to technical scheme of the present invention to be described, although by invention has been described with reference to the preferred embodiments of the present invention, but those of ordinary skill in the art is to be understood that, can make various changes to it in the form and details, and the spirit and scope of the present invention that do not depart from appended claims and limited.
Claims (6)
1, para-amino benzoic acid quasi dipeptide ester, form by following formula:
Wherein, work as R
1During for Bzl, R
2Be Me; Work as R
1Be H, CH
3, CH (CH
3)
2, CH
2CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2OBzl, CH
2COOBzl or CH
2CH
2During COOBzl, R
2Be Bzl.
2, the method for preparing the described para-amino benzoic acid quasi dipeptide ester of claim 1, it is characterized in that: be para-amino benzoic acid (1) and amino acid ester (2) directly coupling in the presence of coupling agent and coupling auxiliary agent, make para-amino benzoic acid quasi dipeptide ester (3), its chemical equation is as follows:
In above-mentioned chemical equation, work as R
1During for Bzl, R
2Be Me; Work as R
1Be H, CH
3, CH (CH
3)
2, CH
2CH (CH
3)
2, CH (CH
3) CH
2CH
3, CH
2OBzl, CH
2COOBzl or CH
2CH
2During COOBzl, R
2Be Bzl.
3, the method for preparing the para-amino benzoic acid quasi dipeptide ester according to claim 2, it is characterized in that: described coupling agent is N, N '-DIC, N, N '-dicyclohexylcarbodiimide, O-benzotriazole-N, N, N ', N '-tetramethyl-urea Tetrafluoroboric acid ester, N-ethyl-N '-dimethylamine propyl carbodiimide or block special condensing agent.
4, the method for preparing the para-amino benzoic acid quasi dipeptide ester according to claim 2 is characterized in that: described coupling auxiliary agent is I-hydroxybenzotriazole, N-hydroxyl-7-azo benzotriazole or N-maloyl imines.
5, the method for preparing the para-amino benzoic acid quasi dipeptide ester according to claim 2 is characterized in that: described coupling temperature is 10～35 ℃.
6, the application of the described para-amino benzoic acid quasi dipeptide ester of claim 1 in the preparation antidiabetic medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102372450A CN101445468B (en) | 2008-12-25 | 2008-12-25 | P-aminobenzoic acid quasi dipeptide ester, method for preparing same and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008102372450A CN101445468B (en) | 2008-12-25 | 2008-12-25 | P-aminobenzoic acid quasi dipeptide ester, method for preparing same and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101445468A true CN101445468A (en) | 2009-06-03 |
| CN101445468B CN101445468B (en) | 2012-02-01 |
Family
ID=40741392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008102372450A Expired - Fee Related CN101445468B (en) | 2008-12-25 | 2008-12-25 | P-aminobenzoic acid quasi dipeptide ester, method for preparing same and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101445468B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107383383A (en) * | 2017-07-21 | 2017-11-24 | 四川大学 | A kind of tree-shaped peptides macromolecular of homochiral and preparation method thereof |
| CN111157739A (en) * | 2019-12-28 | 2020-05-15 | 王贤俊 | IV type collagen antibody latex particle, preparation method and special combined coupling agent thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4533466B2 (en) * | 1995-11-06 | 2010-09-01 | ユニバーシティ オブ ピッツバーグ | Inhibitors of protein isoprenyl transferase |
-
2008
- 2008-12-25 CN CN2008102372450A patent/CN101445468B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107383383A (en) * | 2017-07-21 | 2017-11-24 | 四川大学 | A kind of tree-shaped peptides macromolecular of homochiral and preparation method thereof |
| CN111157739A (en) * | 2019-12-28 | 2020-05-15 | 王贤俊 | IV type collagen antibody latex particle, preparation method and special combined coupling agent thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101445468B (en) | 2012-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4281180A (en) | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | |
| Anderson et al. | The use of esters of N-hydroxysuccinimide in peptide synthesis | |
| US6353124B1 (en) | Therapeutic compound-fatty acid conjugates | |
| Oza et al. | Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors | |
| JP2003226680A (en) | New effective terminal differentiation-inducing agent and its use | |
| JPH06340691A (en) | Peptide | |
| CA1101846A (en) | Derivatives of 4-hydroxy-phenylglycine | |
| Belokon et al. | A new synthesis of enantiomerically pure syn-(S)-β-hydroxy-α-amino acids via asymmetric aldol reactions of aldehydes with a homochiral Ni (II)-glycine/(S)-BPB Schiff base complex | |
| Shiraishi et al. | The structure-activity relationships in coronatine analogs and amino compounds derived from (+)-coronafacic acid | |
| HU177576B (en) | Process for preparing 2-amino-cyclohexane carboxylic acid,its amides and similar compounds | |
| Goto et al. | Sensitive derivatization reagents for optical resolution of carboxylic acids by high performance liquid chromatography with fluorescence detection | |
| Higashiura et al. | Syntheses and properties of optically active 2-substituted taurines | |
| CN101445468B (en) | P-aminobenzoic acid quasi dipeptide ester, method for preparing same and application thereof | |
| TW200528471A (en) | Dipeptide phenyl ethers | |
| WO2024078483A1 (en) | Novel ceramide, preparation method therefor, and use thereof | |
| FÜLÖP | The chemistry of 2-aminocyclopentanecarboxylic acid | |
| Isowa et al. | Synthesis of N δ-Hydroxyornithine | |
| Wilchek et al. | The synthesis of tryptophan peptides | |
| Zeelen et al. | Synthesis of stearoylamino‐acids | |
| Harada et al. | Sterically Controlled Syntheses of Optically Active Organic Compounds. XIX. Asymmetric Syntheses of Amino Acids by the Strecker Reaction | |
| CN102702039A (en) | Process for synthesizing beta-alanyl-taurine | |
| Bennett et al. | Synthesis and properties of (6, 7-dimethoxy-4-coumaryl) alanine: a fluorescent peptide label | |
| Mazaleyrat et al. | Practical resolution of an atropoisomeric α, α-disubstituted glycine with l-phenylalanine cyclohexylamide as chiral auxiliary | |
| CN102659639B (en) | Preparation technology of leonurine | |
| Boyle et al. | Synthesis of novel N-protected hydrophobic phenylalanines and their application in potential antibacterials |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120201 Termination date: 20141225 |
|
| EXPY | Termination of patent right or utility model |